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Usher Syndrome (USH) is a syndromic inherited retinal dystrophy (IRD). It is a clinically and genetically heterogeneous autosomal recessive disorder, characterized by retinitis pigmentosa (RP)^[@CR1]--[@CR3]^ and bilateral sensorineural deafness, with or without vestibular dysfunction.

USH has a prevalence of 3.2 to 6.2 cases per 100000, thus representing the leading genetic cause of combined hearing and vision loss^[@CR4],[@CR5]^. Three different clinical subtypes have been so far identified based on hearing, vestibular and visual symptoms^[@CR6]^. Type 1 (USH1) is the most severe form of USH, characterized by severe congenital deafness, vestibular dysfunction and prepubertal RP onset^[@CR7]^. Deafness is less severe in USH type 2 (USH2), for which the vestibular function remains normal, while RP symptoms generally occur during puberty^[@CR7]^. Finally, USH type 3 (USH3) is characterized by post lingual hearing loss, while the age of RP occurrence is offset between the second to fourth decade and can be subject to variable vestibular dysfunctions^[@CR6]^. Sixteen loci and thirteen disease-causing genes associated with USH have been so far identified (<https://sph.uth.edu/retnet/>), thus demonstrating the wide genetic heterogeneity of this syndrome. Such heterogeneity makes molecular diagnosis with Sanger sequencing of single genes rather challenging, since this particular diagnostic strategy, although accurate, requires a lot of time and resources^[@CR6]^. Microarray technology for the simultaneous detection of known mutations in Usher related genes, instead, has proven to perform poorly, proving diagnostic efficiency as low as 12%, when applied on the Italian population^[@CR8]^. Nevertheless, thanks to the recent availability of next generation sequencing (NGS) in routine genetic testing, it is now possible to simultaneously screen an increasing number of selected genes (targeted NGS), as well as the whole exome or the entire genome. So far, NGS has proven to be a rapid and cost-effective diagnostic method, which is also a useful tool for the identification of novel disease-causing genes^[@CR9]^. Targeted NGS is being currently applied on patients affected by hereditary diseases with high gene heterogeneity, such as Usher syndrome and, both syndromic and non-syndromic, inherited retinal dystrophies^[@CR10]--[@CR13]^.

Deeper understanding of the genetic basis allows further analysis of possible genotype-phenotype correlations. Besides being useful for genetic counselling, such knowledge base is fundamental to an accurate clinical diagnosis and prognosis of individual patients and thus represents an invaluable tool for the development of personalized treatments.

The report describes the phenotypes associated with the mutations detected during genetic testing with targeted NGS. The tests were carried out on a group of 21 consecutive Italian patients from 17 unrelated families affected by Usher syndrome who were seeking genetic counselling.
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This is a retrospective study. The study comprises 21 consecutive Italian patients (15 males and 6 females) from 17 unrelated families with a clinical diagnosis of Usher syndrome who were seeking genetic counselling at the Mauriziano Hospital in Torino, Italy. The pedigrees of the 17 families are reported in Fig. [1](#Fig1){ref-type="fig"}.Figure 1Pedigrees of the families included in the study.

The data collection complies with the Italian law. The study was conducted in accordance with the provisions stated in the Declaration of Helsinki (59th World Medical Association General Assembly; Seoul, Korea; October 2008).

All the patients and their relatives were duly informed about the advantages and limitations of the test and were required to sign informed consent. Detailed medical, personal and family history was obtained from the patients and their relatives, specifically recording the age of onset of deafness, visual deficiency and equilibrium impairment.

In most cases, the available ophthalmological clinical data were composed by slit-lamp anterior segment and fundus examinations, best corrected visual acuity, Goldmann applanation tonometry, electroretinogram (ERG), visual evoked potentials (VEP), visual field test, optic coherence tomography (OCT). A few patients had also sustained colour vision tests, fundus autofluorescence and fluorescein angiography.

DNA analysis {#Sec4}
------------

Within the framework of the Italian rare diseases registry, the diagnostic genetic unit of AOU Careggi in Firenze offers National Health System patients free genetic testing for IRD. Genetic testing is mainly requested to confirm clinical diagnosis, for genetic counselling for patients and their families and to allow participation in gene therapy trials.

Genomic DNA was isolated from peripheral leukocytes, using the QiaSymphony DNA Blood Midi kit on the QIAsymphony SP workstation (Qiagen), according to the manufacturer's protocol.

A custom Haloplex panel was designed using Agilent's online SureDesign tool (<https://earray.chem.agilent.com/suredesign/index.htm>), Targeted NGS of coding regions and exon-intron junctions of a panel of 11 genes were performed: *MYO7A* (MIM 276903)*, CDH23* (MIM 605516)*, PCDH15* (MIM 605514)*, USH1C* (MIM 605242)*, USH1G* (MIM 607696)*, USH2A* (MIM 608400), *ADGVR1* (MIM 602851)*, DFNB31* (MIM 607928)*, CLRN1* (MIM 606397)*, PDZD7* (MIM 612971)*, HARS* (MIM 142810). Genes *ABDH12* (MIM 613599,612674), *CEP250* (MIM 609689) and *CIB2* (MIM 614869) were not included in the panel because mutations in these genes have only been recorded in a few non-Caucasian families. *PDZD7* gene was included because it has been suggested to be a modifier gene in subjects with *USH2A* mutations and potentially involved with *ADGRV1* in digenic USH2^[@CR14]^.

The target regions were captured using the Agilent HaloPlex Target Enrichment System Kits for Illumina Sequencing following Agilent protocols. The captured target libraries were amplified by PCR, quality controlled and quantified using the BioAnalyzer 2100 (Agilent Technologies, Inc. Santa Clare, CA). Equimolar amounts of differentially indexed samples were pooled before pair-ended sequencing at 300 cycles on the Illumina MiSeq platform (Illumina Inc., San Diego, CA, USA). In addition, the deep intronic variant (c.7595-2144A \> G) in intron 40 of *USH2A* gene was searched^[@CR15]^.

The criteria used to distinguish new mutations from polymorphisms is ExAC frequency. We filtered variants with a MAF \< 0.05. All the new mutations reported in this study are not validated at RNA and protein levels.

The new mutations reported were investigated in 48 healthy subjects (20 females, 28 males) with Sanger sequencing.

For the new point mutations leading to aminoacid substitution, pathogenicity predictions from Bioinformatic tools SIFT, PhyloP, AGVGD, MutationTaster and Polyphen2 were compared.

For intronic mutations, although our laboratory cannot validate that the mutations observed indeed affect the splicing process, the bioinformatics tools available predicted all of them to be pathogenic; furthermore the variants were at the exon-intron junction and such variants both at RNA level and in classical genetics are reported to affect the splicing process.

The presence of all pathogenic and likely pathogenic variants detected was confirmed with Sanger sequencing, processed with the automated Core System (Beckman Coulter, Fullerton, CA). After purification, amplicons were sequenced on the 3730 DNA Analyzer (ABI, Foster City, CA). The sequences were assembled and analyzed using SeqScape software (ABI). Variants of unknown pathogenicity were interpreted with Alamut 2.6 (Interactive Biosoftware, Rouen, France), a decision-support software application for medical molecular genetics. The software relies on web-based prediction software, such as Align-GVGD, SIFT, PolyPhen, Mutation Taster (hosted by Interactive Biosoftware). Note that Alamut 2.6 scoring systems provide a predictive evaluation only for missense variants. In selected patients multiplex ligation-dependent probe amplification (MLPA) was also performed. The MLPA reaction (P361-A1/P362-A2 SALSA MLPA kit; MRC Holland, Amsterdam, The Netherlands) was performed according to the manufacturer's recommendations. One microliter of each reaction product was separated on a POP-7 polymer with capillary electrophoresis using the 3730 DNA Analyzer (ABI). Freely available software provided by MRC Holland was used to analyze the MLPA data (Coffalyser; MRC Holland).

When relatives were available (14 families), segregation analysis was performed.
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DNA analysis results were in accordance with the diagnosis for all patients clinically diagnosed with USH. The average of sequencing depth was about \>99.9%. We obtained about 70 variants for each sample. We filtered for function and frequency according to ACMG guidelines^[@CR16]^. We obtained about 1--3 variants for sample that were validated by Sanger sequencing.

Likely causative mutations were identified in three Usher related genes: *USH2A*, *MYO7A, ADGRV1*. For the causative mutations found in this study, reported and novel, there aren't neither *in vivo* functional experiments showing that the mutations cause the USH phenotype, nor *in vitro* experiments showing that the mutations will cause genetic dysfunction.

The results are reported in Table [1](#Tab1){ref-type="table"}. Further heterozygous mutations in Usher related genes were observed in nine patients (Table [2](#Tab2){ref-type="table"}). In Table [3](#Tab3){ref-type="table"} the frequency in our normal population of the new mutation and the pathogenecity prediction from Bioinformatic tools SIFT, PhyloP, AGVGD, MutationTaster and Poluphen2 for the new point mutations leading to aminoacid substitution, are reported. In Fig. [1](#Fig1){ref-type="fig"} the pedigree of the 17 families and the genotypes of the patients and of their relatives are reported.Table 1Patients' phenotypes and mutations identified in Usher genes.FamilyPatientAge\*SexOnset HL (yrs)Onset VI (yrs)GeneMutationProteinReportedSegregation1TO147F1420USH2Ac.2299del(p.Glu767Serfs\*21)HeterozygousReportedYESUSH2Ac.4732C \> T(p.Arg1578Cys)HeterozygousReported2TO235M716USH2Ac.2299del(p.Glu767Serfs\*21)HeterozygousReportedYESUSH2Ac.5603T \> G(p.Phe1868Cys)HeterozygousReported2TO329M616USH2Ac.2299del(p.Glu767Serfs\*21)HeterozygousReportedYESUSH2Ac.5603T \> G(p.Phe1868Cys)HeterozygousReported3TO417M310USH2Ac.2299del(p.Glu767Serfs\*21)HeterozygousReportedYESUSH2A**c.563A \> G(p.Tyr188Cys)**Heterozygous**Novel**4TO558M712USH2Ac.2168-1G \> Cp?HeterozygousReportedNot doneUSH2Ac.9815C \> T(p.Pro3272Leu)HeterozygousReported5TO632MCong6MYO7Ac.4065del(p.His1355Glnfs\*44)HeterozygousReportedYESMYO7Ac.5886_5888del(p.1963del)HeterozygousReported6TO721F210USH2ADel exon 23 \> 32p?HomozygousReportedYES7TO854M630USH2A**Del exon 31 \> 35p?**Heterozygous**Novel**Not doneUSH2Ac.14977_14978del(p. Phe4993Profs\*7)HeterozygousReported8TO948M68USH2ADel exon23 \> 32p?HeterozygousReportedYESUSH2Ac.2299del(p.Glu767Serfs\*21)HeterozygousReported8TO1046F718USH2ADel exon 23 \> 32p?HeterozygousReportedYESUSH2Ac.2299del(p.Glu767Serfs\*21)HeterozygousReported9TO1131M3 mo19MYO7A**c.849 G \> A(p.Met283Ile)**Homozygous**Novel**YES10TO1216M316USH2Ac.1055C \> T(p.Thr352Ile)HeterozygousReportedYESUSH2Ac.10450C \> T(p.Arg3484\*)HeterozygousReported10TO1320F318USH2Ac.1055C \> T(p.Thr352Ile)HeterozygousReportedYESUSH2Ac.10450C \> T(p.Arg3484\*)HeterozygousReported11TO1445M720USH2Ac.269A \> G(p.Tyr90Cys)HeterozygousReportedYESUSH2Ac.14977_14987del(p.Phe4993Profs\*7)HeterozygousReported12TO1533F77USH2Ac.908G \> A(p.Arg303His)HeterozygousReportedYESUSH2Ac.14803C \> T(p.Arg4935\*)HeterozygousReported13TO1612MCong1MYO7Ac.5617C \> T(p.Arg1873Trp)HeterozygousReportedYESMYO7A**c.1935 + 4A \> Tp?**Heterozygous**Novel**13TO1723M18mo4MYO7Ac.5617C \> T(p.Arg1873Trp)HeterozygousReportedYESMYO7A**c.1935 + 4A \> Tp?**Heterozygous**Novel**14TO1830M616USH2Ac.1000C \> T(p.Arg334Trp)HeterozygousReportedYESUSH2A**c.15208G \> T(p.Glu5070\*)**Heterozygous**Novel**15TO1920M11mo17USH2Ac.5933_5940delp.Pro1978Glnfs\*5HomozygousReportedYESUSH2A**c.5950_5960dupp.Tyr1987\***Homozygous**Novel**YES16TO2028F415USH2Ac.908G \> A(p.Arg303His)HomozygousReportedYES17TO2153M538ADGRV1**c.3334G \> Tp.Glu1112\***Homozygous**Novel**Not doneHL = hearing loss; VI = visual impairment; ^\*^Age at counselling and genetic testing; M = male; F = female; yrs = years; mo = months; cong = congenital. Table 2Additional variants in Usher genes.FamilyPatientAge\*SexOnset HL (yrs)Onset VI (yrs)GeneMutationProteinReportedSegregation6TO721F210MYO7Ac.6424G \> Ap.Asp2142AsnHeterozygousReportedYESADGRV1c.6133G \> Ap.Gly2045ArgHeterozygousNovelCDH23c.4858G \> Ap.Val1620MetHeterozygousReported7TO854M630ADGRV1c.11272C \> A(p.Gln3758Lys)HeterozygousNovelNot done9TO1131M3 mo19USH2Ac.1407G \> A(p.Gly4692Arg)HeterozygousReportedYES11TO1445M720CDH23c.4858G \> A(p.Val1620Met)HeterozygousReportedYES12TO1533F77USH2Ac.688G \> A(p.Val230Met)HeterozygousReportedYES13TO1612MCong1ADGRV1c.6133G \> A(p.Gly2045Arg)HeterozygousNovelYES13TO1723M18mo4ADGRV1c.6133G \> A(p.Gly2045Arg)HeterozygousNovelYES14TO1830M616USH2Ac.5858C \> G(p.Ala1953Gly)HeterozygousReportedYESUSH2Ac.14527 A \> G(p.Arg4843Gly)HeterozygousNovel15TO1920M11mo17ADGRV1c.11974G \> A(p.Asp3992 Asn)HeterozygousNovelYESHL = hearing loss; VI = visual impairment; ^\*^Age at counselling and genetic testing; M = male; F = female; yrs = years; mo = months; cong = congenital Table 3New mutations: frequency in control population and pathogenicity predictionChange indbSNPPrediction algorithmsNucleotideProteinIDMAF (%)phyloPSIFTPolyPhen2Mutation TasterAlign GVGD***USH2A***c.563A \> Gp.Tyr188CyNA0Moderately conserved nucleotideDeleteriousProbably damagingDisease causingC0del exon 31- \> 35p.?---------------c.15208G \> Tp.Glu5070\*NA0---------------c.5950_5960dupp.Tyr1987\*NA0---------------***MYO7A***---------------c.849 G \> Ap.Met283IleNA0Moderately conserved nucleotideToleratedBenignDisease causingC0c.1935 + 4 A \> Tp.?NA0---------------***ADGRV1***c.3334 G \> Tp.Glu1112\*NA0---------------MAF = minor allele frequency; SIFT = sorting intolerant from tolerant; PolyPhen2 = polymorphism phenotyping; NA = not applicable.

Phenotype {#Sec7}
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Details of the phenotypes are reported in Table [4](#Tab4){ref-type="table"}.Table 4Clinical characteristics.PatientAge\*SexBCVAAnatomic changesGVFCMEHearing changesVestibular functionOtherTO147FRE: 0.05 LE: 0.04Bilateral cataract, RP sine pigmento,Residual bilateral 10°AbsentBilateral progressive pantonal neurosensory hearing lossSubjective equilibrium impairment in the 5^th^ decadeTO235MRE: 0.2 LE: 0.25Bilateral cataractN/AMacular hole in REBilateral progressive neurosensory hearing lossNo subjective equilibrium impairmentTO329MRE: 0.2 LE: 0.25Bilateral cataract, bilateral pigment depositsResidual bilateral 10°N/ABilateral non progressive post lingual hearing lossNo subjective equilibrium impairmentTO417MRE: 0.4 LE: 0.6Bilateral pigment depositsResidual bilateral 10°N/ABilateral neurosensory hearing lossNo subjective equilibrium impairment Vestibular test normalTwo episodes of absence seizureTO558MRE: 0.8 LE: 0.6Bilateral cataract, bilateral pigment depositsResidual bilateral 20°N/ABilateral neurosensory median and high frequencies hearing lossNo subjective equilibrium impairmentTO632MRE: 0.3 LE: 0.3Bilateral cataract, bilateral pigment depositsRE: Residual isle in temporal-superior, LE: reduction of sensibility and nasal deficitN/ABilateral congenital hearing lossDelayed walking.Vestibular test abnormalTO721FRE: 0.4 LE: 0.2Bilateral pigment deposits, vitreo-macular tractionResidual bilateral \< 10°Present bilateralBilateral congenital moderate/profound hearing lossDelayed walking Vestibular test abnormalTO854MRE: 0.8 LE: 0.4Bilateral cataract, bilateral pigment deposits, peripapillary atrophy, macular pucker,RE: Residual central 6--10° LE: Residual central 10--15°N/ABilateral pan-tonal non progressive severe neurosensory hearing lossVestibular test abnormalMigraine episodesTO948MRE: 0.5 LE: 0.7Bilateral cataract, bilateral pigment deposits, peripapillary atrophy.Residual bilateral 10°N/ABilateral pan tonal severe neurosensory hearing lossVestibular test abnormalTO1046FN/AN/AN/AN/ABilateral moderate hearing lossSubjective equilibrium impairmentTO1131MRE: 0.95 LE: 0.95Bilateral pigment depositsResidual bilateral 20°PresentBilateral congenital progressive severe hearing loss, bilateral cochlear implantNo subjective equilibrium impairment. Walked at 13 monthsTO1216MRE: 1 LE: 1Bilateral pigment deposits and atrophic areasN/APresent bilateralBilateral congenital hearing loss, hearing aidsNo subjective equilibrium impairmentTO1320FRE: 0.9 LE: 0.5Bilateral pigment deposits, optic nerve head drusenResidual bilateral 20°PresentBilateral mild hearing lossNo subjective equilibrium impairment*GJB2* wild-type Headache, recurrent sinusitis and bronchitisTO1445MRE: 1 LE: 1Bilateral cataract, bilateral pigment depositsResidual bilateral 10°AbsentBilateral mild progressive neurosensory hearing lossSubjective equilibrium impairmentNeonatal jaundiceTO1533FN/ABilateral pigment depositsResidual bilateral 20°AbsentBilateral mild high frequencies neurosensory hearing lossNo subjective equilibrium impairment. Vestibular test normalMigraine. *CPT2* gene mutations associated myopathyTO1612MRE: 0.7 LE: 0.5Abnormal macular reflex, pale optic disk, no pigment depositN/APresent LEBilateral congenital hearing loss, cochlear implantDelayed walking (18 months)Pervasive development disorderTO1723MRE: 1 LE: 0.15Bilateral cataract, bilateral pigment deposits, peripheral retinal teleangectasia, vitreous hemorrhage in LE, optic disk drusenResidual bilateral 10°Present LEBilateral congenital severe hearing loss, cochlear implantDelayed walking (24 months) Vestibular test abnormalScleral buckling and vitrectomy in LE for retinal detachment. *GJB2* wild-typeTO1830MRE: 0.55 LE: 0.45Bilateral pigment depositsReduced sensitivity with paracentral scotomatous areasPresent bilateralBilateral progressive neurosensory hearing loss,hearing aidsNo subjective equilibrium impairmentLiver angioma *GJB2* wild-typeTO1920MRE: 0.9 LE: 0.8Bilateral pigment depositsResidual bilateral 10°N/ABilateral progressive mild post lingual neurosensory hearing lossNo subjective equilibrium impairmentDorsal scoliosisTO2028FRE: 0.5 LE: 0.5Bilateral cataract, bilateral pigment depositsResidual bilateral 10°AbsentBilateral progressive mild post lingual neurosensory hearing lossNormalSeveral episodes of loss of consciousness, abnormal EEGTO2153MRE: 0.5 LE: 0.6Bilateral cataract. bilateral pigment depositsResidual bilateral 10°N/ABilateral progressive severe post lingual neurosensory hearing lossNo subjective equilibrium impairmentRE, right eye; LE, left eye; BCVA, best corrected visual acuity; GVF, Goldmann Visual Field; CME, cystoid macular edema; N/A, not available; EEG; electroencephalogram.

Discussion {#Sec8}
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This report retrospectively analyses the clinical and genetic data of 21 consecutive Italian patients from 17 unrelated families affected by Usher syndrome undergoing genetic analysis by targeted NGS of 11 genes (*MYO7A, CDH23, PCDH15, USH1C, USH1G*, *USH2A*, *ADGVR1, DFNB31, CLRN1, PDZD7, HARS*). USH2 syndrome was the most frequent clinical diagnosis, accounting for 81% of the patients, while USH1 was diagnosed in 19%. None of the patients were affected by USH3.

24 likely pathogenic variants - 17 previously reported and 7 novel - were identified in three genes (*USH2A*, *MYO7A*, *ADGRV1*). Five mutations were detected in *MYO7A*, two of which were novel; 18 mutations were identified in *USH2A* (4 of which novel) and one novel homozygous mutation was identified in *ADGRV1*. Additional variants with uncertain pathogenic significance in *USH2A*, *MYO7A*, *ADGRV1*, *CDH23* genes were further identified in 9 patients. In these patients, the additional variants were not considered to be the main causative mutations because two other causative variants were present (reported or novel but with a strong impact at the protein level). We cannot exclude a modifier role for these uncertain variants.

Genetic testing result was in accordance with previous clinical diagnosis or clinical suspicion for all patients. All subjects with USH1 or suspected USH1 displayed biallelic *MYO7A* mutations and all subjects with USH2 presented at least two *USH2A* or two *ADGRV1* mutations. Such results are in line with previous studies that report *MYO7A* and *USH2A* gene mutations being among the most frequent causes of USH1 and USH2^[@CR17]^. The frameshift mutation c.2299delG (p.Glu767Serfs\*21) in the *USH2A* gene was the most frequent in our cohort, since it was detected in 6 patients from four unrelated families. This mutation is quite frequent (0.16 to 0.44) in several cohorts of patients^[@CR18]--[@CR21]^. According to current literature, this is the most common mutation in European patients, accounting for approximately 30% of all European cases of *USH2A* ^[@CR22]^. The high frequency of such mutation has been reported in several different populations and was proven to be the result of an ancestral mutation that has then spread throughout Europe and other continents due to migratory movements^[@CR23]^.

Segregation analysis revealed three patients (TO15, TO18 and TO19) with a *USH2A* allele carrying more than one mutation. This finding underlines the importance of performing segregation analysis on patients suffering from recessive disorders to identify the exact genotype. Although such thoroughness adds up to the costs, it is essential for genetic counselling and reliable family risk evaluation.

All subjects with USH1 and biallelic *MYO7A* mutations were diagnosed with deafness and vestibular function impairment within their first 18 months of life. This lead to an initial clinical diagnosis of myopathy with neurodevelopmental delay in one patient (TO17), while the brother (TO16) was diagnosed with a pervasive developmental disorder. For all patients, deafness was initially attributed to a possible prenatal or postnatal infection. Three patients were tested in early childhood for *GJB2* gene mutations, since this gene is deemed to be the leading cause for hereditary deafness within the European population^[@CR24]^. At the time of diagnosis, the absence of pathogenic variants in *GJB2* gene had, in fact, misled the physician in reinforcing the hypothesis of an infective aetiology of deafness. The parents of two of these patients, having been reassured about a low risk of recurrence, had a second affected child. This further stresses the fundamental importance of providing an exact diagnosis to children affected by deafness. Such diagnosis can be accomplished by offering targeted NGS for syndromic and non-syndromic deafness-related genes whenever prenatal or postnatal infective aetiology is not documented.

Visual symptoms have also proven to occur at an early age, ranging from 1 to 6 years, hence well before the age of 10, as generally observed in USH1 subjects^[@CR25]^. Only patient TO11 had a late onset of visual symptoms, which went unnoticed until he was 19. This patient has a novel homozygous missense mutation in *MYO7A* gene that might have a milder effect on retinal function.

A recent study on the Italian population confirms that hearing and visual impairment generally occur at an earlier age in patients carrying MYO7A mutations compared to those carrying USH2A mutations. The mean age for hearing loss and visual symptoms is generally between 5 ± 1 months and 16 ± 3 years respectively^[@CR26]^.

Patients with USH2 carrying *USH2A* or *ADGRV1* mutations were diagnosed deaf and displayed visual symptoms at an older age compared to subjects with *MYO7A* mutations. Deafness usually occurred between 11 months and 14 years (mean age 5 years) within the reported range 8 months -- 31 years^[@CR27]^, whereas visual impairment generally onsets later, among 10 to 38 year old, (mean 15 ± 8.4 years) again within the reported age range 8--76 (average age 35.5)^[@CR27]^. Two homozygous c.5933_5940del and 5950_5960dup mutations in *USH2A* were detected in patient TO19, whose deafness onset was recorded when he was 11 months old and whose visual symptoms were noticed only later when he was 17 years old.

The age at which the patients with USH2 in our cohort lamented symptoms was generally earlier than what a recent study on Italian patients with USH^[@CR17]^ reports. The study comprises 36 patients (three USH1 and 33 USH2) and reports the average age of visual symptoms onset to be 17.5 ± 8.8 years. OCT revealed macular oedema in 29% of the patients in our study, a comparable percentage of cystoid macular lesions (from 28 to 49% in different studies) were similarly reported in studies on patients with RP^[@CR28]--[@CR30]^.

In conclusion, patients with USH exhibited clinical severity, which appears to be related to the mutated gene and to the specific type of mutation. Homozygosity for deletion from exon 23 to 32 and homozygosity for c.5933_5940del and c.5950_5960dup in *USH2A* were associated with a severe phenotype. It is known that mutations in *USH2A* can lead either to USH2 or to non-syndromic RP. Mutations carried by USH2 patients, tend to be more severe than those found in non-syndromic RP patients^[@CR31],[@CR32]^. Therefore, there is evidence that, even within the USH2 phenotype, there ought be a severity gradient depending on the specific mutation^[@CR33],[@CR34]^. We also observed a *MYO7A* biallelic mutation that was generating a phenotype with vestibular dysfunction, though it entailing milder hearing and visual symptoms. The role of additional heterozygous mutations in other related Usher genes remains to be further investigated.

These results, thus, provide useful data not only for tailored genetic counselling but they also provide additional clues for early clinical diagnosis of patients with Usher syndrome.

Nevertheless, this study present some limits. The heterogeneity of the clinical information available, in fact, did not allow for statistical analysis.
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